Epizyme Inc. (NASDAQ:EPZM)’s share price fell 4.5% during mid-day trading on Wednesday . The company traded as low as $9.96 and last traded at $10.08, with a volume of 109,975 shares traded. The stock had previously closed at $10.55.

A number of brokerages recently issued reports on EPZM. Zacks Investment Research lowered Epizyme from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Epizyme in a research note on Monday, May 9th. Mizuho reduced their target price on Epizyme from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. Leerink Swann restated an “outperform” rating and issued a $39.00 target price on shares of Epizyme in a research note on Tuesday, June 21st. Finally, HC Wainwright restated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. Epizyme has a consensus rating of “Buy” and a consensus price target of $23.11.

The company’s 50 day moving average price is $11.06 and its 200-day moving average price is $10.81. The firm’s market cap is $559.63 million.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.12. On average, equities analysts predict that Epizyme Inc. will post ($2.25) earnings per share for the current fiscal year.

In related news, insider Robert A. Copeland sold 4,000 shares of the business’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $10.03, for a total transaction of $40,120.00. Following the completion of the transaction, the insider now owns 4,000 shares in the company, valued at $40,120. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Other institutional investors have recently modified their holdings of the company. Jennison Associates LLC increased its position in shares of Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares during the last quarter. Casdin Capital LLC purchased a new position in shares of Epizyme during the fourth quarter worth approximately $5,327,000. California Public Employees Retirement System purchased a new position in shares of Epizyme during the fourth quarter worth approximately $2,723,000. Finally, Jennison Associates increased its position in shares of Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock worth $3,262,000 after buying an additional 1,551 shares during the last quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.